RxDoctor Payments DataLook up a doctor →

Wendy Moses, MD

Family Medicine · Shreveport, LANPI 1487681730

Payments from drug & device makers

$16,148in general payments, 2019–2025

Across 1,054 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • Boehringer Ingelheim$950
  • Novo Nordisk$886
  • plus $8K from 52 others

What the payments were for

  • Food & beverage$16,04999%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)250$2,962
AstraZeneca(2 entities)90$1,561
Lilly USA, LLC74$1,207
Pfizer70$1,044
Boehringer Ingelheim65$950
Novo Nordisk55$886
Amgen(2 entities)54$747
GSK44$705
Merck40$567
Takeda Pharmaceuticals U.S.A., Inc.36$538
Axsome Therapeutics, Inc.17$514
Bayer29$504
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC24$343
Johnson & Johnson23$276
Daiichi Sankyo Inc.11$226
Biohaven Pharmaceutical Holding Company Ltd.12$222
Phathom Pharmaceuticals, Inc.10$199
Kowa Pharmaceuticals America, Inc.13$184
Ironshore Pharmaceuticals Inc.8$151
Amarin Pharma, Inc.9$148
Astellas Pharma US Inc4$129
Biohaven Pharmaceuticals, Inc.9$125
Corium, LLC5$121
Sanofi-aventis U.S. LLC9$115
UCB, Inc.1$115
Teva Pharmaceuticals USA, Inc.8$110
Dexcom, Inc.5$108
Supernus Pharmaceuticals, Inc.5$105
Lundbeck LLC5$96
Abbott6$88
Shield Therapeutics Inc5$85
Idorsia Pharmaceuticals US Inc4$77
Exact Sciences4$74
IBSA Pharma Inc.4$72
Corcept Therapeutics3$66
Otsuka America Pharmaceutical, Inc.3$60
Tris Pharma Inc3$54
Shire North American Group Inc4$54
Ardelyx, Inc.3$53
Avanir Pharmaceuticals, Inc.3$49
Collegium Pharmaceutical, Inc.3$47
Upsher-smith Laboratories LLC3$46
Neos Therapeutics, LP3$45
Recor Medical Inc2$37
Abiomed1$32
Arbor Pharmaceuticals, Inc.2$32
Inogen, Inc.2$27
Sumitomo Pharma America, Inc.1$23
Tonix Medicines, Inc.1$22
Vanda Pharmaceuticals Inc.1$21
Xeris Pharmaceuticals, Inc.1$19
Itamar Medical Inc1$18
Harmony Biosciences LLC1$16
Boston Scientific1$16
Adlon Therapeutics L.p.1$16
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$14
Eisai Inc.1$13
Esperion Therapeutics, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,148 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$98,990
Medicare patients
240
Services billed
1,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide137$187,168
OzempicSemaglutide122$152,643
JardianceEmpagliflozin114$101,746
EliquisApixaban34$36,143
LinzessLinaclotide41$33,531
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$26,979
JanuviaSitagliptin Phosphate29$20,406
GlyxambiEmpagliflozin/Linagliptin23$19,347
XareltoRivaroxaban20$16,224
Synjardy XrEmpagliflozin/Metformin Hcl17$15,422
TrulicityDulaglutide13$13,802
Janumet XrSitagliptin Phos/Metformin Hcl22$11,714
FarxigaDapagliflozin Propanediol13$10,670
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$8,989
MovantikNaloxegol Oxalate14$7,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,207$200,969150 claims
Novo NordiskOzempic$886$152,643122 claims
Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr$950$136,515154 claims
PfizerEliquis, Premarin$1,044$39,10146 claims
AbbVieLinzess$2,962$33,53141 claims
MerckJanuvia, Janumet Xr$567$32,11951 claims
GSKTrelegy Ellipta$705$26,97921 claims
AstraZenecaFarxiga, Brilinta$1,561$16,32924 claims
Johnson & JohnsonXarelto$276$16,22420 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$343$6,88413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →